Navigation Links
Helix BioPharma Announces Q1 2009 Financial Results
Date:12/11/2008

for gross proceeds of $11,424,000. Each unit consists of one common share and one-half common share purchase warrant with each whole common share purchase warrant entitling the holder to purchase, subject to adjustment, one common share at a price of $2.36 until 5pm (Toronto time) on October 1, 2011.

The total number of common shares issued as at October 31, 2008 was 53,175,335 (July 31, 2008 - 46,375,335).

At October 31, 2008, the Company's working capital was $26,534,000 (July 31, 2008 - $19,166,000).

Based on our planned expenditures and assuming no material unanticipated expenses, we believe that our cash reserves and expected cash from operations will be sufficient to meet our anticipated cash needs for working capital and capital expenditures for the next twelve months.

The Company will continue to seek additional funding, primarily by way of equity offerings, to carry out its business plan and to minimize risks to its operations. The market, however, for equity financings for companies such as Helix is challenging, and there can be no assurance that additional funding by way of equity financing will be available. The failure of the Company to obtain additional funding on a timely basis may result in the Company reducing, delaying or cancelling one or more of its planned research, development and marketing programs and reducing related personnel, any of which could impair the current and future value of the business. Any additional equity financing, if secured, may result in significant dilution to the existing shareholders at the time of such financing. The Company may also seek additional funding from other sources, including technology licensing, co-development collaborations, and other strategic alliances, which, if obtained, may reduce the Company's interest in its projects or products. There can be no assurance, however, that any alternative sources of funding will be availab
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. Helix BioPharma reports Q2 2008 highlights, financial results
11. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 22, 2014  Neogen Corporation (Nasdaq: NEOG ... quarter of its 2015 fiscal year, which ended Aug. ... net income of $7,839,000 in the first quarter of ... Oct. 30, 2013, earnings per share in the current ... First quarter revenues increased 15% to $67,599,000, ...
(Date:9/22/2014)... September 22, 2014 The US ... mixed note as the Dow Jones Industrial Average finished ... at 4,579.79, down 0.30%. The S&P 500 finished the ... six out of ten sectors finished on a positive ... the day at 751.48, up 0.10%, with the index ...
(Date:9/22/2014)... BETHESDA, Md. , Sept. 22, 2014  Spherix Incorporated ... fostering and monetization of intellectual property, today announced that the ... patent to the Company in the month of September that ... The issued patent is: USRE45,121 , ... 2014 , Filing date: Dec 27, 2012 ...
(Date:9/21/2014)... September 21, 2014 Chemical Sciences ... challenges such as clean air and safe water, ... natural products. Chemists, environmentalists, food scientists, educators, and ... research in the field of Chemistry for the ... Sciences is one of the fastest emerging Sciences, ...
Breaking Biology Technology:Neogen reports 13% net income increase 2Neogen reports 13% net income increase 3Neogen reports 13% net income increase 4Neogen reports 13% net income increase 5Neogen reports 13% net income increase 6Neogen reports 13% net income increase 7Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 2Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 3Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 4Stock Updates on Biotech Industry - Array BioPharma, Enzon Pharma, Alkermes, Amarin, and Synergy Pharma 5Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 2Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 3Chemistry for Global Development during the Open Access Week 2Chemistry for Global Development during the Open Access Week 3
... Inc. (PDL, the Company) (NASDAQ: PDLI ) today ... other conditions, $135 million aggregate principal amount of new convertible ... statement filed with the U.S. Securities and Exchange Commission (SEC) ... the underwriters a 13-day overallotment option to purchase up to ...
... SPRING, Md., May 9, 2011 The U.S. Food and ... public relating to the development of a user fee ...   (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... as a microorganism, plant, or animal cell, while small ...
... 2011 Accuray Incorporated (Nasdaq: ... radiosurgery, announced today that the U.S. Securities and Exchange ... Statement relating to the previously announced acquisition of TomoTherapy ... registration statement will first be mailed to TomoTherapy shareholders ...
Cached Biology Technology:PDL BioPharma, Inc. Announces Proposed $135 Million Public Offering of New Convertible Senior Notes Due 2015 2PDL BioPharma, Inc. Announces Proposed $135 Million Public Offering of New Convertible Senior Notes Due 2015 3PDL BioPharma, Inc. Announces Proposed $135 Million Public Offering of New Convertible Senior Notes Due 2015 4PDL BioPharma, Inc. Announces Proposed $135 Million Public Offering of New Convertible Senior Notes Due 2015 5FDA Requests Input on Development of User Fee Program for Biosimilar and Interchangeable Biological Products 2SEC Declares Accuray Form S-4 Registration Statement Effective in Proposed Acquisition of TomoTherapy 2SEC Declares Accuray Form S-4 Registration Statement Effective in Proposed Acquisition of TomoTherapy 3SEC Declares Accuray Form S-4 Registration Statement Effective in Proposed Acquisition of TomoTherapy 4
(Date:9/22/2014)... fishes that manufacture their own "antifreeze" proteins to ... an unfortunate side effect, researchers report: The protein-bound ... melting even when temperatures warm. , The ... the National Academy of Sciences . , "We ... of the evolution of antifreeze proteins in Antarctic ...
(Date:9/22/2014)... 2014)The Brain & Behavior Research Foundation ... Young Investigator Grants valued at more than ... most promising young scientists. Recipients of the ... will seek to identify causes, improve treatments ... that affect one in four people, including ...
(Date:9/22/2014)... more useful in homes, if they could locate people, ... with cameras and lasers, which have difficulty reliably recognizing ... clutter. A complementary way robots can "sense" what is ... frequency radio-frequency identification (UHF RFID) tags. Inexpensive self-adhesive tags ... to search a room for the correct tag,s signal, ...
Breaking Biology News(10 mins):Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 2Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 3Brain & Behavior Research Foundation awards 200 NARSAD Young Investigator grants 2New RFID technology helps robots find household objects 2New RFID technology helps robots find household objects 3
... Karen Burg and her colleagues in the Institute for ... means of studying the complex behavior of cancer cells ... way doctors treat the disease. With support from ... the researchers are building scaffolds that mimic the three-dimensional ...
... diseases is a hot area of scientific research, primarily ... the context of atherosclerotic disease. Scientists have engineered a ... about the conditions under which nanoparticles accumulate in the ... of myocardial infarction and stroke. In the research, ...
... blood platelets and bone marrow cells to deliver potentially ... genetic disorder Hurler syndrome an often fatal condition ... Scientists from Cincinnati Children,s Hospital Medical Center and the ... their unique strategy for treating the disease the week ...
Cached Biology News:In vitro innovation: Testing nanomedicine with blood cells on a microchip 2In vitro innovation: Testing nanomedicine with blood cells on a microchip 3Mouse study shows gene therapy may be possible cure for Hurler syndrome 2
This antibody detects cdc42 on SDS-PAGE immunoblots....
Goat polyclonal to Nebraska Calf Diarrhea Virus (FITC) ( Abpromise for all tested applications). Antigen: Bovine (Nebraska Calf Diarrhea Virus)....
DNA fragmentation factor & Inhibitor of CAD...
Rabbit polyclonal to Methionine Aminopeptidase 2 ( Abpromise for all tested applications). entrezGeneID: 10988 SwissProtID: P50579...
Biology Products: